Jacob D. Aguirre

Jacob D. Aguirre

Auto-generated profile, based on publicly available information

Jacob D. Aguirre

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2015 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
AKAtul Kumar
Atul Kumar
JAJacob D Aguirre
Jacob D Aguirre
TCTara Ec Condos
Tara Ec Condos
RMR Julio Martinez‐Torres
R Julio Martinez‐Torres
VCViduth K Chaugule
Viduth K Chaugule
HWHelen Walden
Helen Walden
The PARK2 gene is mutated in 50% of autosomal recessive juvenile parkinsonism (ARJP) cases. It encodes parkin, an E3 ubiquitin ligase of the RBR family. Parkin exists in an autoinhibited state that is activated by phosphorylation of its N‐terminal ubiquitin‐like (Ubl) domain and binding of phosphoubiquitin. We describe the 1.8 Å crystal structure of human parkin in its fully inhibited state and identify the key interfaces to maintain parkin inhibition. We identify the phosphoubiquitin‐binding interface, provide a model for the phosphoubiquitin–parkin complex and show how phosphorylation of the Ubl domain primes parkin for optimal phosphoubiquitin binding. Furthermore, we demonstrate that the addition of phosphoubiquitin leads to displacement of the Ubl domain through loss of structure, unveiling a ubiquitin‐binding site used by the E2~Ub conjugate, thus leading to active parkin. We find the role of the Ubl domain is to prevent parkin activity in the absence of the phosphorylation signals, and propose a model for parkin inhibition, optimization for phosphoubiquitin recruitment, release of inhibition by the Ubl domain and engagement with an E2~Ub conjugate. Taken together, this model provides a mechanistic framework for activating parkin.

17 June 2013 in Nature Communications
Verified
Journal Article
Open access
DSDonald E. Spratt
Donald E. Spratt
RMR Julio Martinez-Torres
R Julio Martinez-Torres
YNYeong J. Noh
Yeong J. Noh
PMPascal Mercier
Pascal Mercier
NMNoah Manczyk
Noah Manczyk
GSGary Shaw
Gary Shaw
Mutations in the park2 gene, encoding the RING-inBetweenRING-RING E3 ubiquitin ligase parkin, cause 50% of autosomal recessive juvenile Parkinsonism cases. More than 70 known pathogenic mutations occur throughout parkin, many of which cluster in the inhibitory amino-terminal ubiquitin-like domain, and the carboxy-terminal RING2 domain that is indispensable for ubiquitin transfer. A structural rationale showing how autosomal recessive juvenile Parkinsonism mutations alter parkin function is still lacking. Here we show that the structure of parkin RING2 is distinct from canonical RING E3 ligases and lacks key elements required for E2-conjugating enzyme recruitment. Several pathogenic mutations in RING2 alter the environment of a single surface-exposed catalytic cysteine to inhibit ubiquitination. Native parkin adopts a globular inhibited conformation in solution facilitated by the association of the ubiquitin-like domain with the RING-inBetweenRING-RING C-terminus. Autosomal recessive juvenile Parkinsonism mutations disrupt this conformation. Finally, parkin autoubiquitinates only in cis, providing a molecular explanation for the recessive nature of autosomal recessive juvenile Parkinsonism.

22 December 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JAJacob D. Aguirre
Jacob D. Aguirre
KDKaren M. Dunkerley
Karen M. Dunkerley
PMPascal Mercier
Pascal Mercier
GSGary Shaw
Gary Shaw
Mutations in PARK2 and PARK6 genes are responsible for the majority of hereditary Parkinson’s disease cases. These genes encode the E3 ubiquitin ligase parkin and the protein kinase PTEN-induced kinase 1 (PINK1), respectively. Together, parkin and PINK1 regulate the mitophagy pathway, which recycles damaged mitochondria following oxidative stress. Native parkin is inactive and exists in an autoinhibited state mediated by its ubiquitin-like (UBL) domain. PINK1 phosphorylation of serine 65 in parkin’s UBL and serine 65 of ubiquitin fully activate ubiquitin ligase activity; however, a structural rationale for these observations is not clear. Here, we report the structure of the phosphorylated UBL domain from parkin. We find that destabilization of the UBL results from rearrangements to hydrophobic core packing that modify its structure. Altered surface electrostatics from the phosphoserine group disrupt its intramolecular association, resulting in poorer autoinhibition in phosphorylated parkin. Further, we show that phosphorylation of both the UBL domain and ubiquitin are required to activate parkin by releasing the UBL domain, forming an extended structure needed to facilitate E2–ubiquitin binding. Together, the results underscore the importance of parkin activation by the PINK1 phosphorylation signal and provide a structural picture of the unraveling of parkin’s ubiquitin ligase potential. Significance Parkinson’s disease is a devastating neurodegenerative disorder that can be inherited through mutations in genes encoding the kinase PTEN-induced kinase 1 (PINK1) or the ubiquitin ligase parkin. Parkin exhibits neuroprotective properties by ubiquitinating proteins on damaged mitochondria, leading to their turnover. However, parkin exists in an inactive state that must be alleviated by PINK1 phosphorylation. Therefore, the molecular interpretation of the phosphorylation signal is immensely valuable to our understanding of parkin’s role in mitochondrial maintenance and neuronal fidelity. We present the 3D structure of the phosphorylated inhibitory domain of parkin and describe the structural changes that lead to activation of the enzyme. Alongside the available phosphoubiquitin structure, this study completes a structural picture of PINK1-orchestrated parkin activation in impaired mitochondria.

20 April 2016 in FEBS Letters
Verified
Journal Article
Open access
PDF file
SGSusanna George
Susanna George
JAJacob D. Aguirre
Jacob D. Aguirre
DSDonald E. Spratt
Donald E. Spratt
YBYumin Bi
Yumin Bi
MJMadeline Jeffery
Madeline Jeffery
Patrick  O'DonoghuePatrick O'Donoghue
Patrick O'Donoghue
The activity of the Parkinson's disease‐linked E3 ligase parkin is stimulated by phosphorylation at ubiquitin Ser65 (pUbS65). The role of other ubiquitin phospho‐sites and their kinases are unknown. We produced pUb variants (pS7, pS12, pS20, pS57, pS65) by genetically encoding phosphoserine with the UAG codon. In release factor‐deficient Escherichia coli (ΔRF1), intended to enhance UAG read‐through, we discovered ubiquitin variants lacking the UAG‐encoded residue, demonstrating previously undocumented +3 frame shifting. We successfully purified each pUb variant from mistranslated products. While pUbS20 failed to stimulate parkin, parkin was partially active with pUbS12. We observed significant ubiquitination when pUbS65 was the sole substrate.

30 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ECElizabeth M. Connelly
Elizabeth M. Connelly
ARAnne C. Rintala-Dempsey
Anne C. Rintala-Dempsey
MGMehmet Gundogdu
Mehmet Gundogdu
EFE. Aisha Freeman
E. Aisha Freeman
JKJoanna Koszela
Joanna Koszela
GSGary Shaw
Gary Shaw
Parkin is an E3 ubiquitin ligase implicated in early-onset forms of Parkinson’s disease. It catalyzes a transthiolation reaction by accepting ubiquitin (Ub) from an E2 conjugating enzyme, forming a short-lived thioester intermediate, and transfers Ub to mitochondrial membrane substrates to signal mitophagy. A major impediment to the development of Parkinsonism therapeutics is the lack of structural and mechanistic detail for the essential, short-lived transthiolation intermediate. It is not known how Ub is recognized by the catalytic Rcat domain in parkin that enables Ub transfer from an E2~Ub conjugate to the catalytic site and the structure of the transthiolation complex is undetermined. Here, we capture the catalytic intermediate for the Rcat domain of parkin in complex with ubiquitin (Rcat–Ub) and determine its structure using NMR-based chemical shift perturbation experiments. We show that a previously unidentified α-helical region near the Rcat domain is unmasked as a recognition motif for Ub and guides the C-terminus of Ub toward the parkin catalytic site. Further, we apply a combination of guided AlphaFold modeling, chemical cross-linking, and single turnover assays to establish and validate a model of full-length parkin in complex with UbcH7, its donor Ub, and phosphoubiquitin, trapped in the process of transthiolation. Identification of this catalytic intermediate and orientation of Ub with respect to the Rcat domain provides important structural insights into Ub transfer by this E3 ligase and explains how the previously enigmatic Parkinson’s pathogenic mutation T415N alters parkin activity.

15 September 2023 in Cell
Verified
Journal Article
Open access
KMKevin G. Mark
Kevin G. Mark
SKSriDurgaDevi Kolla
SriDurgaDevi Kolla
JAJacob D. Aguirre
Jacob D. Aguirre
DGDanielle M. Garshott
Danielle M. Garshott
SSStefan Schmitt
Stefan Schmitt
MRMichael Rapé
Michael Rapé